177 related articles for article (PubMed ID: 35687207)
1. Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275).
Francolini G; Loi M; Ciccone LP; Detti B; Di Cataldo V; Pinzani P; Salvianti F; Salvatore G; Sottili M; Santini C; Frosini G; Visani L; Burchini L; Mattioli C; Allegra AG; Valzano M; Cerbai C; Aquilano M; Salvestrini V; Desideri I; Mangoni M; Meattini I; Livi L
Med Oncol; 2022 Jun; 39(8):119. PubMed ID: 35687207
[TBL] [Abstract][Full Text] [Related]
2. Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275).
Francolini G; Loi M; Salvestrini V; Mangoni M; Detti B; Di Cataldo V; Aquilano M; Pinzani P; Salvianti F; Desideri I; Mariotti M; Garlatti P; Stocchi G; Ciccone LP; Lucidi S; Salvatore G; Sottili M; Meattini I; Livi L
Clin Exp Metastasis; 2021 Oct; 38(5):451-458. PubMed ID: 34410545
[TBL] [Abstract][Full Text] [Related]
3. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
[TBL] [Abstract][Full Text] [Related]
4. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
6. Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer.
Ashizawa T; Nagata M; Nakamura S; Hirano H; Nagaya N; Lu Y; Horie S
Sci Rep; 2022 Oct; 12(1):18016. PubMed ID: 36289357
[TBL] [Abstract][Full Text] [Related]
7. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
8. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
9. Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
Cho H; Byun SS; Son NH; Chung JI; Seo WI; Lee CH; Morgan TM; Han KH; Chung JS
Clin Cancer Res; 2024 May; 30(9):1788-1800. PubMed ID: 38587547
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Halabi S; Guo S; Park JJ; Nanus DM; George DJ; Antonarakis ES; Danila DC; Szmulewitz RZ; McDonnell DP; Norris JD; Lu C; Luo J; Armstrong AJ
Clin Cancer Res; 2024 Mar; 30(6):1152-1159. PubMed ID: 38236581
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
12. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R
JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168
[TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.
Marín-Aguilera M; Jiménez N; Reig Ò; Montalbo R; Verma AK; Castellano G; Mengual L; Victoria I; Pereira MV; Milà-Guasch M; García-Recio S; Benítez-Ribas D; Cabezón R; González A; Juan M; Prat A; Mellado B
Cells; 2020 Jan; 9(1):. PubMed ID: 31947623
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
15. Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients.
Schlack K; Seitzer K; Wüstmann N; Humberg V; Grundmann N; Steinestel J; Tiedje D; Rahbar K; Krabbe LM; Bögemann M; Schrader AJ; Bernemann C
Sci Rep; 2022 Jul; 12(1):11846. PubMed ID: 35831403
[TBL] [Abstract][Full Text] [Related]
16. AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel.
Sieuwerts AM; Onstenk W; Kraan J; Beaufort CM; Van M; De Laere B; Dirix LY; Hamberg P; Beeker A; Meulenbeld HJ; Creemers GJ; van Weerden WM; Jenster GW; Nieuweboer AJM; Mathijssen RHJ; de Wit R; Martens JWM; Sleijfer S
Mol Oncol; 2019 Aug; 13(8):1795-1807. PubMed ID: 31180178
[TBL] [Abstract][Full Text] [Related]
17. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Fernandez-Perez MP; Perez-Navarro E; Alonso-Gordoa T; Conteduca V; Font A; Vázquez-Estévez S; González-Del-Alba A; Wetterskog D; Antonarakis ES; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez Sanchez A; Santander C; Sáez MI; Puente J; Tudela J; Martínez A; López-Andreo MJ; Padilla J; Lozano R; Hervas D; Luo J; de Giorgi U; Castellano D; Attard G; Grande E; Gonzalez-Billalabeitia E
Prostate; 2023 Mar; 83(4):376-384. PubMed ID: 36564933
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Total, PTEN
Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C
Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297
[TBL] [Abstract][Full Text] [Related]
19. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ
J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
Gurioli G; Conteduca V; Brighi N; Scarpi E; Basso U; Fornarini G; Mosca A; Nicodemo M; Banna GL; Lolli C; Schepisi G; Ravaglia G; Bondi I; Ulivi P; De Giorgi U
BMC Med; 2022 Jan; 20(1):48. PubMed ID: 35101049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]